MedTrace Logo

L-arginine Versus Sildenafil in Children With Beta Thalassemia Associated With Pulmonary Hypertension

NCT03402191 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2018-08-27

No results posted yet for this study

Summary

This study compares L-arginine Versus Sildenafil as treatment for pulmonary hypertension in Children with Beta Thalassemia

Conditions

Interventions

DRUG

L-arginine

l-arginine for thalassemia with pulmonary hypertension

DRUG

Sildenafil

Sildenafil for thalassemia with pulmonary hypertension

Sponsors & Collaborators

  • Sherief Abd-Elsalam

    lead OTHER

Principal Investigators

  • Sahar El-Haggar, Prof · Tanta University - Faculty of Pharmacy

  • Mohamed El-Shanshoury, Prof · Tanta University Pediatrics Department

  • Osama Abd-rab El-Rasol, Prof · Tanta University Pediatrics Department

  • Tarek Mostafa, Ass Prof · Tanta University-Faculty of pharmacy

  • Eman El-Khateeb, Msc · Tanta University-Faculty of pharmacy

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2023-12-31
Completion
2023-12-31

Countries

  • Egypt

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03402191 on ClinicalTrials.gov